EVMN · Evommune
Conviction · Low · not more likely to lead the S&P 500 over the next three months
Note written ·
The last three months
Down 48.5% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.
Daily closes, to . Red: the note's price line under the older rule, a daily close above $8.62, set on 18 November 2026. The pale line is the 50-day average, $7.13 on .
Price line
A daily close above $8.62, the 11 November 2026 close before the third-quarter report, which would show buying outweighing the dilution and the wait until 2027 data. An acquisition offer or a partnership bringing in non-dilutive cash would also show the shares leading.
A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.
Research onlyNot in the portfolio.
The business · as of
Evommune is a clinical-stage biotech developing drugs for chronic inflammatory diseases: EVO301 for atopic dermatitis and ulcerative colitis, EVO756 for migraine, and the licensed oral degrader EVO570. It sells no product and earns money only from partner payments. It reported no revenue in the quarter to 30 September 2026 and a net loss of $30.9 million.
What is changing, and what follows · as of
- What is changing now
- On 4 November 2026 Evommune licensed EVO570 from Hinova for $30 million upfront. On 5 November 2026 it announced a $30 million share sale at $6.04. Both followed EVO756's Phase 2b failures in June and September 2026.
- What follows for the company
- Third-quarter R&D expense rose to $24.6 million and G&A to $8.8 million. Cash and investments were $262.3 million at 30 September 2026, with a runway the company puts into the second half of 2029.
- What follows for its customers, suppliers and competitors
- EVO301 competes in atopic dermatitis with Dupixent from Regeneron (REGN) and Sanofi (SNY). EVO570 enters the VAV1 degrader field where Novartis (NVS) is already active.
What the price assumes · as of
At the 17 November 2026 close (filed inputs to 12 November 2026), market value is $290 million, P/B 1.2 and free-cash-flow yield −31.4%; P/E is not meaningful and enterprise value is not available. The price values the company slightly above its $251 million of equity. It holds only if the four-quarter cash burn of $91 million is funded without deeper dilution until the 2027 data.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 20 November 2026 close
The last six quarters
- Revenue, latest quarter ($M)
- 0.0
- Revenue, change on a year (%)
- −100.0
- Operating margin (%)
- −133.3
- Free cash flow, four quarters ($M)
- −91.0
- Free-cash-flow yield (%)
- −31.3
All filed numbers
What Evommune reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 0.0 | −100.0 | — |
| first filed | 0.0 | — | — |
| first filed | 0.0 | −100.0 | — |
| first filed | 0.0 | — | — |
| first filed | 10.0 | — | −133.3 |
| first filed | 0.0 | — | — |
| Pre-tax income ($M) | Not reported |
|---|---|
| Net income ($M) four quarters: −113 | −30.9 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +2251.2 |
| Operating cash flow ($M) | −90.4 |
|---|---|
| Capital spending ($M) | 0.6 |
| Free cash flow ($M) | −91.0 |
| Cash and short-term investments ($M) | 169 |
|---|---|
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 251 |
| Market value ($M) | 291 |
|---|---|
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.2 |
| Free-cash-flow yield (%) | −31.3 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 8.2% of shares outstanding sold short, 3.0 days of average trading to cover, −4.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Competitors:
- REGN, SNY, NVS
The thesis
Evommune's shares are more likely to lag the S&P 500 over the next three months. In 2026 its lead drug, EVO756, failed its main goal in two Phase 2b trials. The remaining programs report no new patient data until the second half of 2027. Meanwhile the company loses about $31 million a quarter and has just sold new shares at $6.04. The next scheduled check is the fourth-quarter and full-year report, expected around March 2027.
The business case now rests on three programs that are years from approval. EVO301 is an IL-18 binding protein fusion for atopic dermatitis. EVO570 is an oral VAV1 degrader licensed in November 2026. EVO756 is now being tested in migraine. The company's 12 November 2026 release lists no patient readout from any of them before the second half of 2027. Until then the price depends on cash, dilution and sentiment toward small biotech, with no trial result to move it. The rating is Low because nothing scheduled before February 2027 is likely to change how the market values the pipeline.
Bullish and bearish views on Evommune, Inc.
The bull case on Evommune, Inc. (EVMN), in brief: EVO301 posted strong early efficacy. The bear case: the lead drug failed twice in 2026.
Bull case
- EVO301 posted strong early efficacy. Phase 2a data presented at the EADV dermatology congress in October 2026 showed a 55% drop from baseline in the eczema severity score (EASI) at week 12, against 22% on placebo (p<0.01). No treatment-related serious or severe adverse events were reported (company release, 12 November 2026).
- The cash runway reaches the second half of 2029. Cash, cash equivalents and investments were $262.3 million at 30 September 2026, according to the 12 November 2026 release, before a private placement of about $30 million announced on 5 November 2026.
- The shares trade close to book value. At the 17 November 2026 close (filed inputs to 12 November 2026), market value was $290 million and price to book 1.2, against filed equity of $251 million ($6.08 a share) at 30 September 2026.
- Two covering analysts still see upside. Needham kept a Buy rating on 15 November 2026 and cut its target from $28 to $25. Leerink Partners kept a bullish rating and a $22 target on 16 November 2026.
Bear case
- The lead drug failed twice in 2026. EVO756 missed its primary endpoint in a 160-patient Phase 2b trial in chronic spontaneous urticaria (top-line results, 29 June 2026). It then missed in atopic dermatitis in September 2026, and the company dropped that indication (12 November 2026 release).
- There is no patient data before late 2027. EVO756 migraine top-line results are due in the second half of 2027. The EVO301 Phase 2b in atopic dermatitis starts in mid-2027. EVO570 begins Phase 1 in the first quarter of 2027 (12 November 2026 release).
- Losses and dilution are both rising. Net loss was $30.9 million in the third quarter of 2026, against $12.5 million a year earlier. G&A expense rose to $8.8 million from $3.7 million. The 5 November 2026 placement sold 4,966,889 shares at $6.04, against a February 2026 financing at $27.88 a share.
- There is no revenue. The company reported no revenue in 2026 through 30 September 2026, against $10.0 million from the Maruho EVO756 collaboration in the third quarter of 2025 (10-Q filed 12 November 2026).
- Management incentives were reset lower. On 13 November 2026 the board repriced options on 3,692,840 shares, originally priced at $16.00–26.77, to $7.63. It also approved cash retention awards for three officers, with the second installment tied to a $15.00 share price (8-K, 17 November 2026).
Price setup · as of
The shares closed at $7.02 on 17 November 2026, 78.9% below the 52-week intraday high of $33.20 set on 10 February 2026. The 3-month change is −53.2%, measured from the 19 August 2026 close of $15.01. The September atopic dermatitis failure falls inside that window. The 52-week closing low is $5.10, set on 23 October 2026.
After that low, the shares rallied through the EADV data and the 4 November 2026 Hinova license to close at $8.62 on 11 November 2026. They then fell for four straight sessions after the 12 November 2026 results and the option repricing. The last close is below the 50-day moving average of $7.34 and far below the 200-day average of $17.03 (adjusted daily closes, as of 17 November 2026).
The $6.04 placement price sits between the October low and the last close. A common market view is that biotech stocks trading near cash tend to recover. Across US stocks, no reliable effect has been found so far for what follows a fall of this size.
Catalysts ahead
- ~15 March 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether quarterly losses stay near $31 million and whether the runway guidance into the second half of 2029 holds without another share sale.
- ~31 March 2027 (est.): EVO570 Phase 1 and EVO301 ulcerative colitis Phase 2 trial starts, guided for the first quarter of 2027. Starting on time would show the newly licensed and remaining programs are moving; a delay would push the 2027 data dates further out.
- ~31 December 2027 (est.): EVO756 Phase 2b migraine top-line data, guided for the second half of 2027. The next efficacy readout for EVO756 after two Phase 2b failures, and the first patient data that could change the value placed on the pipeline.
What it trades with · as of
In 2026 the shares moved mainly on the company's own trial readouts: 29 June 2026 (urticaria failure), September (atopic dermatitis failure), October (EVO301 data at EADV) and November (EVO570 license and financing). With no readout due before the second half of 2027, the shares are likely to follow sentiment toward small, loss-making immunology biotechs and funding conditions more than company news.
EVO301 targets atopic dermatitis, the market Dupixent from Regeneron (REGN) and Sanofi (SNY) leads. EVO570 targets the same VAV1 molecular glue approach as Novartis (NVS), according to Fierce Biotech on 5 November 2026. Moves in this kind of stock can be large: the standard deviation of 63-session returns across liquid US stocks was 27% in 2026.
Caveats
- Options on 3,692,840 shares were repriced to $7.63 on 13 November 2026. Exercising them before the end of a 12-month retention period requires paying the original exercise price as a premium. Form 8-K filed 17 November 2026 · as of
- Officer cash retention awards pay half after one year. The second half requires a share price of at least $15.00 by the second anniversary, or a change in control. Form 8-K filed 17 November 2026 · as of
The evidence, claim by claim (8)
- EVO756 missed its primary endpoint in a 160-patient Phase 2b trial in chronic spontaneous urticaria, and development in that indication was stopped. Evommune top-line results release, 29 June 2026 · as of
- EVO756 missed its primary endpoint in a Phase 2b trial in atopic dermatitis in September 2026, and development in that indication was stopped. Evommune third-quarter 2026 results release · as of
- EVO301 reduced EASI by 55% from baseline at week 12, against 22% on placebo (p<0.01), in Phase 2a atopic dermatitis data presented at EADV in October 2026. Evommune third-quarter 2026 results release · as of
- Third-quarter 2026 net loss was $30.9 million ($0.85 a share), against $12.5 million a year earlier; there was no revenue, against $10.0 million a year earlier. Form 10-Q for the third quarter of 2026 · as of
- Cash, cash equivalents and investments were $262.3 million at 30 September 2026, with a cash runway the company guides into the second half of 2029. Evommune third-quarter 2026 results release · as of
- Evommune licensed EVO570 from Hinova for $20 million in cash and $10 million in pre-funded warrants upfront, with milestones and tiered royalties to follow. Form 8-K filed 4 November 2026 · as of
- A private placement of 4,966,889 shares at $6.04 a share raised about $30 million in gross proceeds. Evommune release, 5 November 2026 · as of
- Needham cut its Evommune target from $28 to $25 and kept a Buy rating; Leerink Partners kept a $22 target on 16 November 2026. Needham note 15 November 2026; Leerink Partners note 16 November 2026 · as of
Sources
- Black Friday Get Elite for just $149.00 Claim Now · finviz.com ·
- November 17, 2026 - 8-K: Current report · ir.evommune.com ·
- Evommune signs $1B deal with China's Hinova to enter same molecular glue niche as Novartis · fiercebiotech.com
- Evommune Announces Top line Results from EVO756 Phase 2b Trial in Moderate to Severe Chronic Spontaneous Urticaria · secure.businesswire.com ·
- 185 Aufrufe 185 0 Kommentare 0 Kommentare · wallstreet-online.de
- Evommune Licenses EVO570 for $30 Million and Raises $30 Million · panabee.com
Related · shared themes
CGON
CG Oncology
CG Oncology shares are modestly more likely to beat the S&P 500 over three months after its drug cretostimogene cut bladder-cancer…
ORKA
Oruka Therapeutics
Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely…
SLS
SELLAS Life Sciences Group
SELLAS Life Sciences is modestly more likely to lead the S&P 500 over three months after its Phase 3 REGAL leukemia trial met its…
XNCR
Xencor
Xencor's shares are modestly more likely to beat the S&P 500 over three months on XmAb819's 45.5% kidney-cancer response rate and cash…